KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.

Tony Mok,William E. Lawler,Merrill Kingman Shum,Shaker R. Dakhil, Alexander I. Spira,Fabrice Barlesi,Martin Reck,Marina Chiara Garassino,David R. Spigel,Delia Alvarez, Thian Kheoh, William Paxton,Richard C. Chao,Enriqueta Felip

Journal of Clinical Oncology（2021）

引用 14|浏览2

暂无评分

摘要

TPS9129Background: Despite significant advances in chemotherapy and immunotherapy for advanced NSCLC, the majority of pts ultimately develop progressive disease associated with poor outcomes. KRAS ...

查看译文

关键词

lung cancer,adagrasib,docetaxel,non-small-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要